In vitro tests for haematotoxicity:: Prediction of drug-induced myelosuppression by the CFU-GM assay

被引:19
作者
Pessina, A
Albella, B
Bayo, M
Bueren, J
Brantom, P
Casati, S
Croera, C
Parchment, R
Parent-Massin, D
Schoeters, G
Sibiri, Y
Van den Heuvel, R
Gribaldo, L
机构
[1] Univ Milan, Inst Microbiol, I-20133 Milan, Italy
[2] CIEMAT, E-28040 Madrid, Spain
[3] British Ind Biol Res Assoc Int, Carshalton SM5 4DS, Surrey, England
[4] Commiss European Communities, Joint Res Ctr, Inst Hlth & Consumer Protect, ECVAM, I-21020 Ispra, VA, Italy
[5] Wayne State Univ, Detroit, MI 48202 USA
[6] Technopole, ESMISAB, F-29280 Plouzane, France
[7] Vlaamse Instelling Technol Onderzoek, B-2400 Mol, Belgium
来源
ATLA-ALTERNATIVES TO LABORATORY ANIMALS | 2002年 / 30卷
关键词
acute neutropenia; CFU-GM assay; maximum tolerated dose; myelotoxicity;
D O I
10.1177/026119290203002S11
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In a prevalidation study, a Standard Operating Procedure (SOP) for human and mouse in vitro tests was developed, for evaluating the potential haematotoxicity of xenobiotics in terms of their direct, adverse effects on the myeloid colony-forming unit (CFU-GM). Based on the adjustment of the mouse-derived maximum tolerated dose (MTD), a prediction model was set up to calculate the human MTD, and an international blind trial was designed to apply this model to the clinical neutropenia of 23 drugs including 17 antineoplastics. The model correctly predicted the human MTD for 20 drugs out of the 23 (87%). This high percentage of predictivity, and the reproducibility of the SOP testing, confirmed the scientific validation of this model, and suggested promising applications for developing and validating other in vitro methods for use in haematotoxicology.
引用
收藏
页码:75 / 79
页数:5
相关论文
共 16 条